Nanopharmaceuticals Market Global Business Forecast with Major Key Companies Abbott, GlaxoSmithKline, Eli Lilly and Company, Astrazeneca, Novavax, Stryker Corporation, OSI Pharmaceuticals

The global nanopharmaceuticals market size was valued at US$ 28,434.3 million in 2017, and is expected to exhibit a CAGR of 22.1 % over the forecast period (2018 – 2026).

Nanopharmaceuticals are used in various conditions such as cancer, neurological disorders, and other diseases. Moreover, high prevalence of cancer globally, is expected to drive the market growth. According to World Health Organization (WHO), September 2018 factsheet, around 9.6 million deaths occurred due to cancer, and the disease was second leading cause of death, globally.

Increasing incidences of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease is expected to propel growth of the nanopharmaceuticals market over the forecast period. According to the World Alzheimer Report 2015, around 46 million people were diagnosed with dementia worldwide in 2015, which was estimated to increase to around 131.5 million by 2050. However, possible toxicity issues, and lack of regulatory guidelines are expected to hinder the market growth. The P&T Community Journal, Volume 42, December 2017, stated an example of carbon-based nanopharmaceuticals demonstrating toxicity in several in vitro and in vivo studies. The mechanism behind toxicity is assumed oxidative stress and others.

Request A Sample Copy Of This Report:
https://www.coherentmarketinsights.com/insight/request-sample/2485

Key manufacturers in the region focuses on developing and innovating new drugs for meeting the needs of patients, which is expected to bolster the market growth over the forecast period. For instance, in October 2012, Celgene Corporation, a U.S. based company, received approval from U.S. Food and Drug Administration (FDA) for Abraxane (paclitaxel protein-bound particles for injectable suspension), which is used for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.

Moreover, key players in the market are focused on receiving the U.S. Food and Drug Administration (FDA) approval for novel products to treat patients. For instance, in May 2017, NovoNodisk received Food and Drug Administration (FDA) approval for glycopegylated Rebinyn, which is used to control bleeding and bleeding management in patients diagnosed with hemophilia B.

Key Players

Major players operating in the global nanopharmaceuticals market include Abbott, GlaxoSmithKline plc., Eli Lilly and Company, Astrazeneca plc., Novavax, Inc., Stryker Corporation, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Tanabe Pharma Corporation, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma Inc., Navidea Biopharmaceuticals, Inc., AbbVie Inc., AMAG Pharmaceuticals, Amgen Inc., Astellas Pharma Inc., Celgene Corporation, Gilead Sciences, Inc., JOHNSON & JOHNSON, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Hoffmann-La Roche AG, Sanofi S.A, Shire Plc., and Teva Pharmaceuticals Industries Limited.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/2485

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.